MIMETAS Revenue and Competitors
Estimated Revenue & Valuation
- MIMETAS's estimated annual revenue is currently $22.3M per year.
- MIMETAS's estimated revenue per employee is $170,000
- MIMETAS has 131 Employees.
- MIMETAS grew their employee count by -1% last year.
MIMETAS Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is MIMETAS?
High-throughput Human Disease and Tissue Models MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.keywords:N/A
Number of Employees
Employee Growth %
CN Bio Tissues, Mimetas Insphero, Ascendance Bio, Kirkstall , Hurel , Synvivo , Axosim and Nortis. This Organs-on-chips Market report covers...
LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in...
Mimetas BV participating in 325m cancer funding. © Oncode Institute. 20.04.2022 by tg. Organ-on-chip disease model specialist Mimentas BV participates in a...
Emulate, CN Bio, Tissuse, Mimetas, Insphero, Ascendance Bio, Kirkstall, Hurel, Synvivo, Axosim, Nortis. Geographical Analysis: North America, ...
... Analysis, Technology and Global Industry Trends by 2027 Top Key Vendors-REPROCELL, 3D Biotek, Nano3D Biosciences, MIMETAS.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|